Clinical trials: Psychotropic Drugs
Child Behavior Disorders
Safer Use of Antipsychotics in Youth
This study tests the effectiveness of an intervention treatment algorithm vs. usual care control in a practical clinical trial. Control arm providers will receive a standard medication alert in the electronic medical record (EMR)…
- Trial name
- SUAY (NCT03448575)
- Testing
- Control - Provider Medication Alert Only, Intervention - Alert + CAP Review AND Enhanced BH Access
- Where
- 4 sites in United States
- Volunteers
- 733 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Depression, Anxiety
Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial.
- Trial name
- UHS (NCT01632267)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Assurex Health Inc.
Major Depressive Disorder With Suicidal Ideation With Intent
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
- Trial name
- NCT04722666
- Testing
- MIJ821 Intravenous Injection
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Safety and Efficacy of Cariprazine in Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104779
- Testing
- Cariprazine
- Where
- 41 sites in United States, Colombia and 2 more
- Volunteers
- 446 people
- Sponsor
- Forest Laboratories
Schizophrenia
A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.
- Trial name
- NCT01626885
- Testing
- MP-214
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Tanabe Pharma Corporation
Medication Adherence, Bipolar Disorder
Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)
Psychotropic-related weight gain is a common concern among patients with bipolar disorder (BD). This concern affects an individual's satisfaction with treatment and may lead to reduced adherence and illness relapse.
- Trial name
- Zip Ad (NCT01293825)
- Testing
- ziprasidone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia
Safety and Efficacy of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
- Trial name
- NCT01625000
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 512 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.
- Trial name
- NCT01625897
- Testing
- MP-214, Risperidone
- Where
- Japan
- Volunteers
- 125 people
- Sponsor
- Tanabe Pharma Corporation
Staff Attitude, Dementia
Changing Talk Online (CHATO) Study
Objectives AIM 1. Establish acceptability and preliminary efficacy of online CHATO modules through pilot testing with NH staff. AIM 2. Develop and pilot test the data collection tool with consultant and advisory panel input.
- Trial name
- NCT03849937
- Testing
- Changing Talk Online (CHATO)
- Where
- 2 sites in United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Schizophrenia
Long-term Study of Cariprazine in Patients With Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.
- Trial name
- NCT01104792
- Testing
- Cariprazine
- Where
- 86 sites in United States, Colombia and 4 more
- Volunteers
- 752 people
- Sponsor
- Forest Laboratories
Polypharmacy, Dementia
A Patient-facing Tool to Reduce Opioid-Psychotropic Polypharmacy in People Living With Dementia (PLWD)
The goal of this project is to address central nervous system-active polypharmacy (CNS polyRx) in people living with dementia (PLWD) through focus groups and an educational intervention.
- Trial name
- NCT05628181
- Testing
- Educational nudge intervention
- Where
- 2 sites in United States
- Volunteers
- 129 people
- Sponsor
- University of Michigan
Schizophrenia
Long-Term Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.
- Trial name
- NCT01626872
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 254 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia
Safety and Efficacy of Cariprazine in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104766
- Testing
- Cariprazine, Aripiprazole
- Where
- 58 sites in United States, Romania and 2 more
- Volunteers
- 617 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder (MDD)
Genomics Used to Improve DEpression Decisions
Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.
- Trial name
- GUIDED (NCT02109939)
- Testing
- GeneSight Psychotropic
- Where
- 61 sites in United States
- Volunteers
- 1,398 people
- Sponsor
- Assurex Health Inc.
Hypercapnia, Ventilatory Depression
Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation
Opioids can decrease breathing and co-administration of benzodiazepines with opioids can further decrease breathing. It is unknown whether certain other drugs also decrease breathing when co-administered with opioids.
- Trial name
- NCT04310579
- Testing
- Oxycodone and Midazolam, Oxycodone, Paroxetine, and Quetiapine
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
Drug Toxicity Psychotropic Agents Psychostimulants
Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)
Ryanodex is being investigated as a potential adjuvant treatment for people suffering from psychostimulant drug-induced toxicity (PDIT), a life-threatening medical condition that results mainly from the abuse of certain illicit…
- Trial name
- NCT03189433
- Testing
- Ryanodex (dantrolene sodium) for injectable suspension
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Eagle Pharmaceuticals, Inc.
Methamphetamine Use Disorder
Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
This study will evaluate the behavioral effects of methamphetamine during maintenance on placebo, duloxetine, methylphenidate and duloxetine combined with methylphenidate using sophisticated human laboratory methods.
- Trial name
- NCT04178993
- Testing
- Methamphetamine, Methylphenidate, Duloxetine
- Where
- 2 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Craig Rush
Depression
Emotional and Cognitive Control in Late-Onset Depression
This study may help identify how abnormalities in brain systems that control the ability to ignore irrelevant information may contribute to the development of depression in older adults.
- Trial name
- NCT01728194
- Testing
- Escitalopram, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Schizophrenia
A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.
- Trial name
- NCT01626859
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Tanabe Pharma Corporation